NCT00556465

Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy

Study of N-Acetylcysteine for Treatment of Overt Diabetic Nephropathy

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Shiraz University of Medical Sciences · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Diabetic nephropathy has become the single most frequent cause of end-stage renal disease. On a molecular level, at least five major pathways have been implicated in glucose-mediated vascular and renal damage and all of these could reflect a single hyperglycaemia-induced process of overproduction of reactive oxygen species. Recent studies have shown that inflammation, and more specifically pro-inflammatory cytokines play a determinant role in the development of micro- vascular diabetic complications, most of the attention has been focused on the implications of TNF-α in the setting of diabetic nephropathy. Glutathione is the most abundant low-molecular-weight thiol, and Glutathione/ glutathione disulfide is the major redox couple in animal cells. N-acetylcysteine is effective precursors of cysteine for tissue Glutathione synthesis. Not only does N-acetylcysteine exhibit antioxidant properties, but it may also counteract the glycation cascade through the inhibition of oxidation. N-acetylcysteine can also reduce the apoptosis elicited by reactive oxygen species . Indeed, N-acetylcysteine has been shown to inhibit reactive oxygen species induced mesangial apoptosis and to be able to protect cells from glucose-induced inhibition of proliferation.

Conditions

• Diabetic Nephropathy
• Chronic Kidney Disease
• Diabetes Type 2

Interventions

Type	Name	Description
DRUG	N-acetylcysteine	600 mg of effervescent N-acetylcysteine tablet twice per day for three months

Timeline

• Start date: 2007-01-01
• Completion: 2007-06-01
• First posted: 2007-11-12
• Last updated: 2007-11-12

Locations

1 site across 1 country: Iran